关注
Heikki Kuusanmäki
Heikki Kuusanmäki
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
在 helsinki.fi 的电子邮件经过验证
标题
引用次数
引用次数
年份
Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia
HLM Koskela, S Eldfors, P Ellonen, AJ van Adrichem, H Kuusanmäki, ...
New England Journal of Medicine 366 (20), 1905-1913, 2012
8592012
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
HLM Rajala, S Eldfors, H Kuusanmäki, AJ Van Adrichem, T Olson, ...
Blood, The Journal of the American Society of Hematology 121 (22), 4541-4550, 2013
3282013
Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3
EM Haapaniemi, M Kaustio, HLM Rajala, AJ van Adrichem, L Kainulainen, ...
Blood, The Journal of the American Society of Hematology 125 (4), 639-648, 2015
2942015
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ...
Haematologica 105 (3), 708, 2020
1352020
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
O Dufva, M Kankainen, T Kelkka, N Sekiguchi, SA Awad, S Eldfors, ...
Nature communications 9 (1), 1567, 2018
1302018
Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia
M Kontro, H Kuusanmäki, S Eldfors, T Burmeister, EI Andersson, ...
Leukemia 28 (8), 1738-1742, 2014
1262014
Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia
E Andersson, H Kuusanmäki, S Bortoluzzi, S Lagström, A Parsons, ...
Leukemia 30 (5), 1204-1208, 2016
922016
Implementing a functional precision medicine tumor board for acute myeloid leukemia
D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ...
Cancer discovery 12 (2), 388-401, 2022
912022
Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia
S Eldfors, H Kuusanmäki, M Kontro, MM Majumder, A Parsons, H Edgren, ...
Leukemia 31 (1), 51-57, 2017
522017
Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing
MM Majumder, R Silvennoinen, P Anttila, D Tamborero, S Eldfors, ...
Oncotarget 8 (34), 56338, 2017
442017
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
H Kuusanmäki, O Dufva, M Vähä-Koskela, AM Leppä, J Huuhtanen, ...
Blood 141 (13), 1610-1625, 2023
402023
Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing
PO Pietarinen, T Pemovska, M Kontro, B Yadav, JP Mpindi, EI Andersson, ...
Blood cancer journal 5 (5), e309-e309, 2015
352015
In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
S Laukkanen, T Grönroos, P Pölönen, H Kuusanmäki, J Mehtonen, ...
Blood cancer journal 7 (9), e604-e604, 2017
322017
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
A Ianevski, J Lahtela, KK Javarappa, P Sergeev, BR Ghimire, P Gautam, ...
Science advances 7 (8), eabe4038, 2021
312021
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
H Kuusanmäki, O Dufva, E Parri, AJ van Adrichem, H Rajala, ...
Oncotarget 8 (57), 97516, 2017
302017
Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
BS White, SA Khan, MJ Mason, M Ammad-Ud-Din, S Potdar, D Malani, ...
NPJ precision oncology 5 (1), 71, 2021
242021
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
H Kuusanmäki, S Kytölä, I Vänttinen, T Ruokoranta, A Ranta, ...
Haematologica 108 (7), 1768, 2023
222023
Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
PO Pietarinen, CA Eide, P Ayuda-Durán, S Potdar, H Kuusanmäki, ...
Oncotarget 8 (14), 22606, 2017
192017
Endogenous and combination retinoids are active in myelomonocytic leukemias
O Di Martino, H Niu, G Hadwiger, H Kuusanmaki, MA Ferris, A Vu, ...
haematologica 106 (4), 1008, 2021
182021
Identification of novel regulators of STAT3 activity
E Parri, H Kuusanmäki, AJ van Adrichem, M Kaustio, K Wennerberg
PloS one 15 (3), e0230819, 2020
172020
系统目前无法执行此操作,请稍后再试。
文章 1–20